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OBJECTIVES: The use of multimodal analgesic management has been implemented
forminimizing adverse events and to improve thepatient recovery processwhichwill
have a significant impact on clinical and economic outcomes. The aim of this study
was to develop an economic assessment of parecoxib, ketorolac andmorphine for the
treatment of postoperative pain (POP) for patients after total abdominal hysterectomy
at the Social Security Mexican Institute (IMSS) from an institutional perspective.
METHODS: A Bayesian decision-tree model was developed to simulate costs and
health outcomes over a 6-day time period in patients treated with multimodal anal-
gesic. Comparators assessed were: morphine (61.5 mg/day) plus parecoxib (40 mg/
day); morphine (61.5 mg/day) plus ketorolac (90 mg/day) and morphine (61.5mg/day)
alone. The effectiveness measure was: percentage of successful response without
adverse events(AE) meeting the highest possible score for patient’s global evaluation
survey (excellent). This survey has been previously validated in Mexico. Costs and
resource usewere collected fromhospital records related to patients undergoing total
abdominal hysterectomy at IMSS in 2008 (n98). Transition probabilities were col-
lected from international published literature andmodel was calibrated according to
international pharmacoeconomics guidelines. One way and probabilistic sensitivity
analyses were performed by Monte Carlo Simulation second-order approach.
RESULTS: Percentageof successful responsewithoutAE resulted forparecoxib in35%,
followed by ketorolac with 24% and morphine with 21%. Estimated cost per patient
treated were lower for ketorolac (US$ 5,309.20) followed by morphine (US$5,343.96)
andparecoxib (US$5,375.78). Nomeaningful statistical differenceswere found in costs
among competing alternatives (p0.05). ICER for additional successful response was
US$ 601.29 for parecoxib against keterolac. Acceptability curves showed that pare-
coxib is the most cost-effective therapy with 90% at a willingness to pay of US$4,500.
CONCLUSIONS: Parecoxib represents a cost-effective analgesic alternative for POP
management in patients who underwent abdominal hysterectomy at the IMSS.
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OBJECTIVES: Treatment of vasomotor symptoms (VMS) inwomenwith breast can-
cer (BC) represents a challenge while the use of hormone replacement therapy
(HRT) in these patients could be not suitable. The purpose of this study was to
estimate the cost-effectiveness of pharmacological treatments for VMS in BC pa-
tients from an institutional perspective. METHODS: A Markov model was per-
formed to estimate health and economic consequences in a time horizon of five
years (quarterly cycles). Effectiveness measures were: reduction of hot flashes
events and QALY’s gained. Comparators assessed were: conjugated estrogens (CE;
0.625mg/day, only used in hysterectomized women), CEmedroxyprogesterone
(2.5mg0.625m/day, only used in non-hysterectomized women), tibolone (2.5mg/
day), no treatment (no candidates to HRT) and desvenlafaxine (100mg/day) as ref-
erence treatment in all indications. Transition probabilities were collected from
published data. Resource use was obtained from clinical files (n140) from Insti-
tutoMexicano del Seguro Social (IMSS) and includes pharmacological treatment for
VMS, screening for HRT eligibility and side effect management. Official institu-
tional costs were used. Probabilistic sensitivity analyses were performed and ac-
ceptability curves were constructed. RESULTS: Compared to no treatment, des-
venlafaxine resulted more costly (US$1,072.68), but avoided 2,753.8 more hot
flashes (ICERUS$0.39/additional hot flash avoided) and gained 0.75 QALY=s
(ICERUS$1,430.24/QALY gained) in no candidates to HRT. In hysterectomized
women, desvenlafaxine cost was US$2,723.76 and dominates CE (incremental:
US$354.64; 441.45 hot flashes, -0.16 QALY=s) and tibolone (incremental:
US$564.94; 811.74 hot flashes; -0.21 QALY=s). In non-hysterectomized women,
desvenlafaxine cost was US$2,866.51 and dominated tibolone (US$3,522.33;
2,297.82 hot flashes and 0.59 QALY=s) and CEmedroxyprogesterone (incremental:
US$855.34;1,764.87 hot flashes; -0.38 QALY=s). Acceptability curves showed that
regardless willingness to pay, desvenlafaxine is likely to be cost-effective against
competing alternatives. CONCLUSIONS: At IMSS, the management of VMS with
desvenlafaxine is a cost-saving alternative for both hystererctomized and non-
hysterectomized BC patients, as well as cost-effective for no candidates to HRT.
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OBJECTIVES: To evaluate the cost-effectiveness of an intervention, Advancing Bet-
ter Living for Elders (ABLE), which was shown to reduce mortality in community-
dwelling elders in a randomized trial. METHODS: 319 community-living older
adults randomized to ABLE or no-treatment control group, were included in the
economic analysis. ABLE involved occupational and physical therapy home and
telephone sessions and home modifications (e.g., grab bars) to address functional
difficulties over 12months. Using ahome-care agency perspective, the incremental
cost-effectiveness ratio (ICER) was expressed as the additional cost to bring about
one additional year of life. To account for potential variations in costs of imple-
menting ABLE in different settings, two models were developed: cost of imple-
menting ABLE and cost 10%. Probabilistic sensitivity analysis was conducted to
account for variation onmodel parameters. Confidence intervals for the ICERswere
calculated using the Fieller theorem method. RESULTS: Total cost of ABLE per
participant after discounting was $908. In the secondary cost-effectiveness analy-
ses total cost after discounting equaled (10%) $999. By 2 years, there were 30
deaths (9 in ABLE and 21 in Control). Life year saved for ABLE was .944 compared to
.868 for the intervention. Under assumptions ofmodels 1 and 2 the additional costs
for 1 additional year of life were $12,985 (95% CI: $4,637-$87,905); and $14,271 (95%
CI: $5,068-$107,539); respectively. CONCLUSIONS: This economic evaluation sug-
gests that investment in this program may be worth while depending on ones
willingness to pay. However, confidence intervals varied widely due to small effect
in reducing mortality.
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OBJECTIVES: We have examined the impact of long term disability costs arising
from increased use of IVF treatments in relation to multiple births reductions in
Canada. METHODS: Using the Canadian Fertility Cost Model we estimated the
potential cost savings of reducing the number ofmultiple pregnancies in Canada. A
series of probabilistic analyses were performed to account for the effect of uncer-
tainty in long-term outcomes and disability costs on the cost effectiveness of re-
ducing multiple births. Values for disability rates were sampled from a beta distri-
bution and costs were sampled from a log-normal distribution. Simulation results
were generated by simultaneously varying long-termdisability rates and costs. The
outcomes included age-specific net total costs, lifetime disability costs, and incre-
mental costs per live birth. RESULTS: Assuming reductions in multiple birth rates
equal to those reached by selected European countries, we estimated that, over the
next five years in Canada, the multiple birth rates could be reduced from 28.8% to
13.4%. Using Monte-Carlo simulations, the potential cost savings range from $150
million to $558million, and the reduction in over-all incremental cost per live birth
range from $8,560 to $31,897. The proportions of children with lifetime disabilities
range from 6.0% to 24.0% for current practice, and 4.3% to 17.3% assuming reduc-
tions inmultiple births. Forwomen under 35, aged 35-39, and over 40, reductions in
over-all incremental cost range from ($9,555 - $35,616), ($7,814 - $29,977) and
($6,031 - $22,543), respectively. The bulk of cost reductions (ranging from 50% to
87%) would be attributable to reductions in disability costs. CONCLUSIONS: Our
analysis shows that a reduction in multiple births would result in potential cost
savings. The amount of variation in the long term outcomes and disability costs
make the projections, nevertheless, highly unstable.
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OBJECTIVES:More than 8.8 million children under 5 die globally before they reach
the age of five. In Kenya, under fivemortality rate was 74 per 1000 children in 2008.
To improve care for seriously ill children, a multifaceted approach employing
guidelines, training, supervision, feedback and facilitationwas developed, for brev-
ity called the Emergency Triage and Treatment Plus (ETAT) strategy.We assessed
the costs and efficiency of delivery of the ETAT strategy in district hospitals in
Kenya. METHODS: A cost-effectiveness analysis from the provider’s perspective
was conducted alongside a cluster randomized study that compared the delivery of
ETAT in four district hospitals in Kenya to four control district hospitals receiving
a partial version of the intervention between 2005 and 2009. Effectiveness of the
interventionwasmeasured using 14 processmeasures that capture improvements
in quality of care and span the assessment, diagnosis and treatment on admission
in children under five. Economic costs were estimated through interviews with
implementers of the intervention, accounting and clinical record reviews. An an-
nual discount rate of 3% was used and one way sensitivity analyses were used to
assess uncertainty. Incremental cost-effectiveness ratios (ICERs) were defined as
the cost per percentage improvement in quality of care. RESULTS: The cost per
child admission was US$ 54.74 in intervention hospitals compared to US$ 31.06 in
control hospitals, while quality of care as measured by the 14 process measures
was 23.05% higher in intervention hospitals than in the control hospitals. These
results suggest an additional cost of US$ 0.85 to achieve a percentage improvement
in quality of care. CONCLUSIONS: The delivery of ETAT as a multifaceted inter-
vention yields significant improvements in quality of care but at a higher cost.
Knowing what value decision makers place on quality improvement would be
useful in making decisions about their adoption explicit.
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OBJECTIVES: To estimate the average (CER) and incremental (ICER) cost-effective-
ness ratios of surfactant rescue treatment of premature infants with Respiratory
Distress Syndrome (RDS) who are covered by the New Generation Medical Insur-
ance . METHODS: A cost-effectiveness evaluation was conducted from the per-
spective of the Mexican Ministry of Health (SSA). The comparisons were between
bovine surfactant therapy and the alternative of not using it. A decision treemodel
with a two-year time horizon was used, where the measurements of effectiveness
were life years gained (LYG) and quality adjusted life years (QALY). The effective-
ness figures are taken from a systematic review, the resource usage patterns were
obtained from data registered in the SSA hospital files on care, and costs from
official sources in SSA 2009. A 5% discount rate was considered for costs and health
outcomes. Deterministic and probabilistic analyses were conducted. RESULTS:
ICER ratios for surfactant therapy per LYG and per QALY were $61,392 and $62,110,
respectively. CONCLUSIONS: Surfactant therapy was confirmed as a cost-effective
strategy, in accordance toWHO criteria of 3 Per-capita GDP per QALY in premature
infants with RDS in Mexico.
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OBJECTIVES:To estimate the cost effectiveness of dienogest versusGnRHanalogue
(GnRH-a) for the treatment of endometriosis-associated chronic pelvic pain in Slo-
vakia from a payer perspective. METHODS: A cost-utility Markov model based on
results of randomized controlled trial (AU19) was adapted to a Slovakian setting.
The AU19 trial, which compared dienogest and GnRH-a (leuprolide) in the treat-
ment of endometriosis-associated chronic pelvic pain over a 6 month period,
showed no statistically significant differences in response rates. The dienogest
annual relapse rate was derived from 52-weeks extension study, while relapse
rates for the GnRH-awere derived from the literature. Local cost data was based on
published price lists, clinical guidelines, product labels and expert opinion. QoL
related utilities were derived from individual patient SF-36 scores from AU19 da-
taset. Effectiveness was measured in quality-adjusted life years (QALY). Time ho-
rizon was set at 2 years and a payers’ perspective was adopted. Discount rate was
5% per year for both costs and effects according to valid Ministry of Health (MoH)
guidelines for health economic evaluation. Both one-way and probabilistic sensi-
tivity analyses were performed. RESULTS: Dienogest showed that it was cost-
effective compared to a GnRH-a, with an overall cost reduction of 506 € and a
QALY gain of 0.002 per patient. Cost reduction was due to both the differences in
the average drug cost during the two year period (GnRH-a: 1 248 € and dienogest:
969 €) and the average laparoscopy cost (GnRH-a: 274 € and dienogest: 103 €). In
probabilistic sensitivity analysis 69 % of simulations were below 18 000 €/QALY,
which is the officially published threshold for willingness to pay in Slovakia.
CONCLUSIONS: Dienogest is a cost-effective alternative to GnRH analogue for the
treatment of endometriosis-associated chronic pelvic pain in a Slovakian setting.
Individual’s Health – Patient-Reported Outcomes & Preference-Based Studies
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OBJECTIVES: Failure to pick up a newly prescribed medication from the pharmacy
is referred to as primary nonadherence. The objective of this retrospective cohort
study is to evaluate primary nonadherence in an integrated closed-network health
care setting. METHODS: All new electronic prescriptions written over a 3-month
period for 11 pre-specified drug classes were identified using electronic health care
data. A prescription was considered new if no medications in the same drug class
were dispensed during the prior year. Patientswere excluded from the study if they
did not have continuousmembership and drug benefits during the 12months prior
and 3 months after the prescription order date, became pregnant during the study
period or were missing age or gender information. Primary nonadherence was
defined as the failure to fill prescriptionswithin 90 days from the day itwaswritten.
Descriptive statistics were used to compare characteristics of adherent prescrip-
tions to nonadherent prescriptions using t-tests and chi-square tests for continu-
ous and categorical variables, respectively. RESULTS: A total of 616,401 new pre-
scriptions were written for 430,098 patients. The overall primary nonadherence
ratewas 8%and themajority of prescriptionswere filled on the sameday as the day
itwaswritten. Nonadherence rateswere slightly higher inmales and older patients
(p0.01).Warfarin products (2%) and anti-infectives (2%) had the lowest nonadher-
ence rates, while analgesics (21%) had the highest nonadherence rate (p0.01). The
primary nonadherence ratewas highest amongprescribers in emergencymedicine
(11%) (p0.01). CONCLUSIONS: This is one of the largest studies examining primary
nonadherence. Primary nonadherence rates found in this study are similar to those of
previous studies using data from a comparable healthcare setting. These results may
be helpful in identifying prescription characteristics associated with higher rates of
primary nonadherence for intervention purposes in the clinical setting.
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OBJECTIVES:Numerous factors pertaining to poormedication adherence in chron-
ically ill patients are well documented, but the paucity of studies concerning ex-
periences during the early treatment course represents a significant knowledge
gap. Interventions targeting this crucial initial phase can significantly influence
long-term adherence and outcomes. An international panel conducted a compre-
hensive, systematic review of the published literature documenting risk factors
related to initial adherence.METHODS: A systematic literature search of Pubmed,
PsychInfo, and Web of Science covered published articles from 1966-2010. Two
independent reviewers abstracted eligible studies through a validated quality in-
strument, documentingmethodological details and factors associated with adher-
ence problems. Articles targeting a variety of behavioral factors were deemed rel-
evant if presenting primary data and quantitative findings following initial
prescriptions. RESULTS: Our search identified 283 potentially relevant publica-
tions; upon full review, 38met eligibility criteria. Themean Nichols quality assess-
ment score was 46.1 (range 11-74), with excellent concordance between indepen-
dent reviewers (r0.923, p0.001). Prevalent terminology defining early
pharmacotherapy was first-fill or initial adherence, yet articles rarely referred to
the very first prescription. Instead, authors examined periods covering 2 weeks to
several years from the index fill, typically the first one to six months. Factors
commonly associated with initial adherence were therapeutic alliance and pro-
vider communication (n9), psychiatric symptoms or disease severity (n6), med-
ication cost/copayments (n5), along with patient demographics and polyphar-
macy. Few studies reported specific health system factors, such as pharmacy
location/information, prescribing provider licensure, or other non-patient
dynamics. CONCLUSIONS: Despite the implications for chronic medication adher-
ence and clinical outcomes, few articles directly examined issues associated with
initial adherence. Notwithstanding this lack of information, many observed risk
factors are amenable to potential interventions, establishing a solid foundation for
appropriate ongoing behaviors. Future research should continue investigating
questions pertaining to initial prescriptions, emerging treatment barriers, and or-
ganizational efforts to promote better long-term adherence.
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OBJECTIVES:Many people underuse themedication prescribed to them for chronic
conditions which undermines their care. Often this underuse is related to the cost
of prescriptions andmay be exacerbated in patients with a traditionally low socio-
economic status. In addition, it has been found that underuse is lower among
patients who express higher satisfaction with the medical care received. We ex-
amined self reported cost-related medication underuse in a sample of black and
white Medicare beneficiaries, and investigated whether racial differences in cost-
related underuse could be explained by differences in satisfaction with care after
controlling for other factors that affect underuse.METHODS: Cross sectional tele-
phone survey of 1031 Medicare beneficiaries 65 years old and older living in Jeffer-
son County, Alabama. Bivariate and multivariable analyses were used to identify
factors associated with delaying or not filling prescriptions because of cost (cost-
related underuse). RESULTS: Of the respondents who had cost-related underuse,
15% were white and 23% were black. Racial disparities were not explained by sat-
isfaction, although low satisfaction was positively associated with cost-related
underuse (adjusted OR1.41, p0.07). In particular, low satisfaction with “expla-
nation on what to do after the doctor visit” was significantly associated with cost-
related underuse. Among 847 who reported adequate income, blacks were 2 times
more likely to have underuse than whites (20% vs 12%, adjusted OR1.9, p.05).
Racial differences in cost-related underuse in the 184 beneficiarieswith inadequate
income were not significant. CONCLUSIONS: Satisfaction with care does not ex-
plain the racial differences, although it has a positive impact on underuse. These
findings suggest that even among those with an income adequate to pay for basic
needs, cost-related underuse is reported by 1 in 6 Medicare beneficiaries. More
research is needed to explain racial disparities in underuse of prescription drugs,
even among beneficiaries who report incomes adequate to meet their needs.
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OBJECTIVES: To evaluate the impact of patient characteristics, behaviors and atti-
tudes on teriparatide adherence in a Medicare Part D plan with a coverage gap.
METHODS: Medicare Part D plan members 18 years and older with at least one
claim for teriparatide in 2009 and continuous enrollment January 1, 2009 – Decem-
ber 31, 2009 were identified in an administrative claims database. A questionnaire
was mailed to members that met study criteria. Descriptive analyses were con-
ducted to evaluate the characteristics of the study population. Logistic regression
analyses were conducted to identify factors that predicted discontinuation with
teriparatide. RESULTS:Out of the 3656mailed questionnaires, 522 (14%) were com-
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